Medium chain triglyceride formulation comprising transplatin as the therapeutic agent are prepared as described in Example A9 with the exception that the JNK inhibitor is replaced with transplatin
A Phase I clinical trial launched in 2015 to evaluate BPC-157s safety and pharmacokinetics in healthy volunteers was marked as completed but never published, with the results withdrawn without explanation (typically a red flag- if anyone has a scoop, do share!)
Although ultrasonography has enabled the in situ evaluation of 1D profile of solid stresses within glioblastoma tumors [111], the estimation of both the isotropic and anisotropic components of the stress tensor exerted on cells and tissues remained elusive until recently
While rarely problematic, travelers carrying peptides should be prepared to explain their purpose
Folate Health Professional Fact Sheet.
At our clinic, patients who come in with chronic GI inflammation, SIBO residuals, or a history of NSAID-induced gastritis are the group most likely to report subjective improvement on BPC-157 within the first 30 days
